In this article, we will discuss Selinexor (Dosage Overview). So, let’s get started.
Selinexor (XPOVIO™) is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this
indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
The recommended starting dosage of XPOVIO is 80 mg (four 20 mg tablets) taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.
The recommended starting dosage of dexamethasone is 20 mg taken orally with each dose of XPOVIO on Days 1 and 3 of each week. For additional information regarding the administration of dexamethasone, refer to its prescribing information.
If a dose of XPOVIO is missed or delayed, instruct patients to take their next dose at the next regularly scheduled time. If a patient vomits a dose of XPOVIO, the patient should not repeat the dose and the patient should take the next dose on the next regularly scheduled day.
Recommended Monitoring for Safety
Monitor complete blood count (CBC), standard blood chemistry, and body weight at baseline and during treatment as clinically indicated. Monitor more frequently during the first two months of
Recommended Concomitant Treatments
Advise patients to maintain adequate fluid and caloric intake throughout treatment.
Consider intravenous hydration for patients at risk of dehydration.
Provide prophylactic concomitant treatment with a 5‐HT3 antagonist and/or other anti‐nausea agents prior to and during treatment with XPOVIO.